Aptus Clinical announces the first patient has been dosed in the Artelo Biosciences’ CAReS Phase 1b/2a study in cancer anorexia

Aptus Clinical, as the full service CRO provider for the Phase 1b/2a Cancer Appetite Recovery Study (CAReS), has assisted Artelo Biosciences in the planning and running of this important study which investigates the potential for ART27.13 (a peripherally synthetic cannabinoid…

Want to know more about our Site Monitoring and Oversight Service?

Great to see additional UK funding to support potentially life-changing advanced therapies.

Advanced Therapy Treatment Centre network awarded £9.5m further investment The UK Government grant will support new and existing projects until March 2022.  Funding will ensure that the positive impact of the ATTC network continues; further optimising the UK ecosystem for…

Aptus Clinical announces recruitment has started for COSMIC-19

      Press Release – August 13, 2020 Alderley Park-based Aptus Clinical Ltd today announced that recruitment has started on the innovative COSMIC-19 study, which they believe will help transform and shape clinical trial monitoring in the future. COSMIC-19…

Read our white paper on the clinical development challenges in oncology

 Optimising Early Clinical Development Strategies in Oncology According to the largest analysis of almost 7,500 clinical and regulatory phase transitions, the likelihood of an oncology drug progressing from Phase I clinical testing is 5%, the lowest of the 14 major…

Proud to be part of the ATTC Network

The Advanced Therapy Treatment Centre Industry Advisory Group brings together 39 leading companies, including Aptus Clinical, who work collaboratively with the NHS to navigate common challenges and support routine clinical adoption of advanced therapies in the UK. https://www.theattcnetwork.co.uk/case_studies/industry-involvement-in-the-attc-programme

Covid-19 update

In light of updated UK government advice, we have decided to trigger our business continuity plan which focuses on keeping our staff safe by working from home whilst continuing to deliver projects supported through virtual ways of working. Remote working…

Aptus Clinical and Alderley Park benefit from Northern Powerhouse Investment Fund

The Northern Powerhouse Investment Fund which is delivered by British Business Bank, has invested a total of £2.5m into businesses based at Alderley Park, Cheshire, the UK’s largest single site life science campus. The £2.5m invested into businesses at Alderley…

Renaissance of interest in medicines modulating ECS: Rising to the challenge

Steve McConchie, CEO at Aptus Clinical shares his analysis on cannabinoid medicines, with Andy Yates of Artelo Biosciences, in Pharmafile. The body’s endocannabinoid system (ECS) consists of receptors and chemical messengers located in the central and peripheral nervous system, forming…

Aptus Clinical selected as clinical CRO by Artelo Biosciences

Aptus Clinical has been appointed full service clinical CRO partner by Artelo Biosciences Inc. (through their fully owned UK subsidiary, Trinity R&D Ltd.) to deliver the upcoming Phase 1B/2A trial of their synthetic cannabinoid, ART27.13. This latest agreement builds on…